S&P 500   3,768.25 (-0.72%)
DOW   30,814.26 (-0.57%)
QQQ   311.86 (-0.79%)
AAPL   127.14 (-1.37%)
MSFT   212.65 (-0.17%)
FB   251.36 (+2.33%)
GOOGL   1,727.62 (-0.19%)
AMZN   3,104.25 (-0.74%)
TSLA   826.16 (-2.23%)
NVDA   514.38 (-2.58%)
BABA   243.46 (+0.20%)
CGC   33.39 (-3.55%)
GE   11.33 (-2.83%)
MU   80.72 (-0.71%)
AMD   88.21 (-2.84%)
T   29.17 (-0.41%)
NIO   56.27 (-7.56%)
F   9.83 (-3.34%)
ACB   12.04 (+0.67%)
BA   204.32 (-2.66%)
DIS   171.44 (-1.15%)
NFLX   497.98 (-0.58%)
GILD   63.33 (+1.49%)
S&P 500   3,768.25 (-0.72%)
DOW   30,814.26 (-0.57%)
QQQ   311.86 (-0.79%)
AAPL   127.14 (-1.37%)
MSFT   212.65 (-0.17%)
FB   251.36 (+2.33%)
GOOGL   1,727.62 (-0.19%)
AMZN   3,104.25 (-0.74%)
TSLA   826.16 (-2.23%)
NVDA   514.38 (-2.58%)
BABA   243.46 (+0.20%)
CGC   33.39 (-3.55%)
GE   11.33 (-2.83%)
MU   80.72 (-0.71%)
AMD   88.21 (-2.84%)
T   29.17 (-0.41%)
NIO   56.27 (-7.56%)
F   9.83 (-3.34%)
ACB   12.04 (+0.67%)
BA   204.32 (-2.66%)
DIS   171.44 (-1.15%)
NFLX   497.98 (-0.58%)
GILD   63.33 (+1.49%)
S&P 500   3,768.25 (-0.72%)
DOW   30,814.26 (-0.57%)
QQQ   311.86 (-0.79%)
AAPL   127.14 (-1.37%)
MSFT   212.65 (-0.17%)
FB   251.36 (+2.33%)
GOOGL   1,727.62 (-0.19%)
AMZN   3,104.25 (-0.74%)
TSLA   826.16 (-2.23%)
NVDA   514.38 (-2.58%)
BABA   243.46 (+0.20%)
CGC   33.39 (-3.55%)
GE   11.33 (-2.83%)
MU   80.72 (-0.71%)
AMD   88.21 (-2.84%)
T   29.17 (-0.41%)
NIO   56.27 (-7.56%)
F   9.83 (-3.34%)
ACB   12.04 (+0.67%)
BA   204.32 (-2.66%)
DIS   171.44 (-1.15%)
NFLX   497.98 (-0.58%)
GILD   63.33 (+1.49%)
S&P 500   3,768.25 (-0.72%)
DOW   30,814.26 (-0.57%)
QQQ   311.86 (-0.79%)
AAPL   127.14 (-1.37%)
MSFT   212.65 (-0.17%)
FB   251.36 (+2.33%)
GOOGL   1,727.62 (-0.19%)
AMZN   3,104.25 (-0.74%)
TSLA   826.16 (-2.23%)
NVDA   514.38 (-2.58%)
BABA   243.46 (+0.20%)
CGC   33.39 (-3.55%)
GE   11.33 (-2.83%)
MU   80.72 (-0.71%)
AMD   88.21 (-2.84%)
T   29.17 (-0.41%)
NIO   56.27 (-7.56%)
F   9.83 (-3.34%)
ACB   12.04 (+0.67%)
BA   204.32 (-2.66%)
DIS   171.44 (-1.15%)
NFLX   497.98 (-0.58%)
GILD   63.33 (+1.49%)
Log in
NASDAQ:APTO

Aptose Biosciences Competitors

$4.40
+0.01 (+0.23 %)
(As of 01/15/2021 12:00 AM ET)
Add
Compare
Today's Range
$4.33
Now: $4.40
$4.52
50-Day Range
$4.03
MA: $4.75
$7.02
52-Week Range
$3.92
Now: $4.40
$9.25
Volume707,737 shs
Average Volume1.04 million shs
Market Capitalization$390.90 million
P/E RatioN/A
Dividend YieldN/A
Beta1.62

Competitors

Aptose Biosciences (NASDAQ:APTO) Vs. BCRX, ATRA, KRYS, ALEC, CLLS, and PCVX

Should you be buying APTO stock or one of its competitors? Companies in the industry of "biological products, except diagnostic" are considered alternatives and competitors to Aptose Biosciences, including BioCryst Pharmaceuticals (BCRX), Atara Biotherapeutics (ATRA), Krystal Biotech (KRYS), Alector (ALEC), Cellectis (CLLS), and Vaxcyte (PCVX).

BioCryst Pharmaceuticals (NASDAQ:BCRX) and Aptose Biosciences (NASDAQ:APTO) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, profitability, valuation, risk and earnings.

Insider and Institutional Ownership

72.0% of BioCryst Pharmaceuticals shares are held by institutional investors. Comparatively, 52.2% of Aptose Biosciences shares are held by institutional investors. 4.3% of BioCryst Pharmaceuticals shares are held by insiders. Comparatively, 6.3% of Aptose Biosciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Risk and Volatility

BioCryst Pharmaceuticals has a beta of 3.03, indicating that its stock price is 203% more volatile than the S&P 500. Comparatively, Aptose Biosciences has a beta of 1.62, indicating that its stock price is 62% more volatile than the S&P 500.

Analyst Ratings

This is a summary of current ratings and target prices for BioCryst Pharmaceuticals and Aptose Biosciences, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
BioCryst Pharmaceuticals03702.70
Aptose Biosciences00703.00

BioCryst Pharmaceuticals presently has a consensus price target of $9.2143, indicating a potential upside of 4.71%. Aptose Biosciences has a consensus price target of $11.2857, indicating a potential upside of 156.49%. Given Aptose Biosciences' stronger consensus rating and higher probable upside, analysts clearly believe Aptose Biosciences is more favorable than BioCryst Pharmaceuticals.

Valuation and Earnings

This table compares BioCryst Pharmaceuticals and Aptose Biosciences' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BioCryst Pharmaceuticals$48.83 million31.82$-108,900,000.00($0.94)-9.36
Aptose BiosciencesN/AN/A$-26,280,000.00($0.52)-8.46

Aptose Biosciences has lower revenue, but higher earnings than BioCryst Pharmaceuticals. BioCryst Pharmaceuticals is trading at a lower price-to-earnings ratio than Aptose Biosciences, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares BioCryst Pharmaceuticals and Aptose Biosciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
BioCryst Pharmaceuticals-233.45%-328.70%-71.11%
Aptose BiosciencesN/A-49.53%-46.65%

Summary

Aptose Biosciences beats BioCryst Pharmaceuticals on 9 of the 12 factors compared between the two stocks.

Atara Biotherapeutics (NASDAQ:ATRA) and Aptose Biosciences (NASDAQ:APTO) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, profitability, valuation, risk and earnings.

Profitability

This table compares Atara Biotherapeutics and Aptose Biosciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Atara BiotherapeuticsN/A-94.86%-82.17%
Aptose BiosciencesN/A-49.53%-46.65%

Risk and Volatility

Atara Biotherapeutics has a beta of 2.65, indicating that its stock price is 165% more volatile than the S&P 500. Comparatively, Aptose Biosciences has a beta of 1.62, indicating that its stock price is 62% more volatile than the S&P 500.

Insider and Institutional Ownership

52.2% of Aptose Biosciences shares are held by institutional investors. 4.3% of Atara Biotherapeutics shares are held by insiders. Comparatively, 6.3% of Aptose Biosciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Valuation and Earnings

This table compares Atara Biotherapeutics and Aptose Biosciences' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Atara BiotherapeuticsN/AN/A$-290,980,000.00($5.67)-3.28
Aptose BiosciencesN/AN/A$-26,280,000.00($0.52)-8.46

Aptose Biosciences is trading at a lower price-to-earnings ratio than Atara Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current ratings and target prices for Atara Biotherapeutics and Aptose Biosciences, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Atara Biotherapeutics03702.70
Aptose Biosciences00703.00

Atara Biotherapeutics presently has a consensus price target of $34.25, indicating a potential upside of 84.04%. Aptose Biosciences has a consensus price target of $11.2857, indicating a potential upside of 156.49%. Given Aptose Biosciences' stronger consensus rating and higher probable upside, analysts clearly believe Aptose Biosciences is more favorable than Atara Biotherapeutics.

Summary

Aptose Biosciences beats Atara Biotherapeutics on 8 of the 10 factors compared between the two stocks.

Krystal Biotech (NASDAQ:KRYS) and Aptose Biosciences (NASDAQ:APTO) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, profitability, risk, dividends and earnings.

Profitability

This table compares Krystal Biotech and Aptose Biosciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Krystal BiotechN/A-10.72%-10.40%
Aptose BiosciencesN/A-49.53%-46.65%

Volatility and Risk

Krystal Biotech has a beta of 1.2, indicating that its share price is 20% more volatile than the S&P 500. Comparatively, Aptose Biosciences has a beta of 1.62, indicating that its share price is 62% more volatile than the S&P 500.

Insider & Institutional Ownership

73.1% of Krystal Biotech shares are held by institutional investors. Comparatively, 52.2% of Aptose Biosciences shares are held by institutional investors. 27.4% of Krystal Biotech shares are held by company insiders. Comparatively, 6.3% of Aptose Biosciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Earnings & Valuation

This table compares Krystal Biotech and Aptose Biosciences' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Krystal BiotechN/AN/A$-19,090,000.00($1.20)-56.54
Aptose BiosciencesN/AN/A$-26,280,000.00($0.52)-8.46

Krystal Biotech is trading at a lower price-to-earnings ratio than Aptose Biosciences, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of current ratings and recommmendations for Krystal Biotech and Aptose Biosciences, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Krystal Biotech00503.00
Aptose Biosciences00703.00

Krystal Biotech presently has a consensus target price of $97.25, indicating a potential upside of 43.33%. Aptose Biosciences has a consensus target price of $11.2857, indicating a potential upside of 156.49%. Given Aptose Biosciences' higher possible upside, analysts plainly believe Aptose Biosciences is more favorable than Krystal Biotech.

Alector (NASDAQ:ALEC) and Aptose Biosciences (NASDAQ:APTO) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, profitability, risk, dividends and earnings.

Profitability

This table compares Alector and Aptose Biosciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Alector-757.78%-53.86%-31.44%
Aptose BiosciencesN/A-49.53%-46.65%

Volatility and Risk

Alector has a beta of 1.08, indicating that its share price is 8% more volatile than the S&P 500. Comparatively, Aptose Biosciences has a beta of 1.62, indicating that its share price is 62% more volatile than the S&P 500.

Insider & Institutional Ownership

61.5% of Alector shares are held by institutional investors. Comparatively, 52.2% of Aptose Biosciences shares are held by institutional investors. 13.9% of Alector shares are held by company insiders. Comparatively, 6.3% of Aptose Biosciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Earnings & Valuation

This table compares Alector and Aptose Biosciences' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Alector$21.22 million63.00$-105,390,000.00($1.71)-9.87
Aptose BiosciencesN/AN/A$-26,280,000.00($0.52)-8.46

Aptose Biosciences has lower revenue, but higher earnings than Alector. Alector is trading at a lower price-to-earnings ratio than Aptose Biosciences, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of current ratings and recommmendations for Alector and Aptose Biosciences, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Alector00703.00
Aptose Biosciences00703.00

Alector presently has a consensus target price of $33.6667, indicating a potential upside of 99.57%. Aptose Biosciences has a consensus target price of $11.2857, indicating a potential upside of 156.49%. Given Aptose Biosciences' higher possible upside, analysts plainly believe Aptose Biosciences is more favorable than Alector.

Summary

Aptose Biosciences beats Alector on 7 of the 11 factors compared between the two stocks.

Cellectis (NASDAQ:CLLS) and Aptose Biosciences (NASDAQ:APTO) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, profitability, risk, dividends and earnings.

Profitability

This table compares Cellectis and Aptose Biosciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Cellectis-110.52%-23.56%-16.69%
Aptose BiosciencesN/A-49.53%-46.65%

Volatility and Risk

Cellectis has a beta of 2.59, indicating that its share price is 159% more volatile than the S&P 500. Comparatively, Aptose Biosciences has a beta of 1.62, indicating that its share price is 62% more volatile than the S&P 500.

Insider & Institutional Ownership

33.3% of Cellectis shares are held by institutional investors. Comparatively, 52.2% of Aptose Biosciences shares are held by institutional investors. 16.4% of Cellectis shares are held by company insiders. Comparatively, 6.3% of Aptose Biosciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Earnings & Valuation

This table compares Cellectis and Aptose Biosciences' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cellectis$22.99 million57.12$-102,090,000.00($2.41)-12.83
Aptose BiosciencesN/AN/A$-26,280,000.00($0.52)-8.46

Aptose Biosciences has lower revenue, but higher earnings than Cellectis. Cellectis is trading at a lower price-to-earnings ratio than Aptose Biosciences, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of current ratings and recommmendations for Cellectis and Aptose Biosciences, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Cellectis11402.50
Aptose Biosciences00703.00

Cellectis presently has a consensus target price of $27.20, indicating a potential downside of 12.00%. Aptose Biosciences has a consensus target price of $11.2857, indicating a potential upside of 156.49%. Given Aptose Biosciences' stronger consensus rating and higher possible upside, analysts plainly believe Aptose Biosciences is more favorable than Cellectis.

Summary

Aptose Biosciences beats Cellectis on 8 of the 13 factors compared between the two stocks.

Vaxcyte (NASDAQ:PCVX) and Aptose Biosciences (NASDAQ:APTO) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, profitability, risk, dividends and earnings.

Earnings & Valuation

This table compares Vaxcyte and Aptose Biosciences' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
VaxcyteN/AN/A$-50,270,000.00N/AN/A
Aptose BiosciencesN/AN/A$-26,280,000.00($0.52)-8.46

Analyst Recommendations

This is a summary of current ratings and recommmendations for Vaxcyte and Aptose Biosciences, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Vaxcyte00403.00
Aptose Biosciences00703.00

Vaxcyte presently has a consensus target price of $48.00, indicating a potential upside of 86.77%. Aptose Biosciences has a consensus target price of $11.2857, indicating a potential upside of 156.49%. Given Aptose Biosciences' higher possible upside, analysts plainly believe Aptose Biosciences is more favorable than Vaxcyte.

Insider & Institutional Ownership

70.6% of Vaxcyte shares are held by institutional investors. Comparatively, 52.2% of Aptose Biosciences shares are held by institutional investors. 6.3% of Aptose Biosciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Profitability

This table compares Vaxcyte and Aptose Biosciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
VaxcyteN/AN/AN/A
Aptose BiosciencesN/A-49.53%-46.65%

Summary

Aptose Biosciences beats Vaxcyte on 4 of the 7 factors compared between the two stocks.


Aptose Biosciences Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
BioCryst Pharmaceuticals logo
BCRX
BioCryst Pharmaceuticals
1.1$8.80+2.4%$1.55 billion$48.83 million-11.58Analyst Upgrade
Heavy News Reporting
Atara Biotherapeutics logo
ATRA
Atara Biotherapeutics
1.6$18.61+1.3%$1.45 billionN/A-4.03
Krystal Biotech logo
KRYS
Krystal Biotech
1.5$67.85+2.2%$1.34 billionN/A-45.84Analyst Upgrade
High Trading Volume
ALEC
Alector
1.3$16.87+7.9%$1.34 billion$21.22 million-7.56Analyst Report
Heavy News Reporting
Cellectis logo
CLLS
Cellectis
0.8$30.91+0.1%$1.31 billion$22.99 million-16.44
PCVX
Vaxcyte
1.8$25.70+0.5%$1.31 billionN/A0.00Analyst Downgrade
Insider Selling
Heavy News Reporting
PASG
Passage Bio
1.3$28.24+5.6%$1.29 billionN/A0.00
Coherus BioSciences logo
CHRS
Coherus BioSciences
1.4$17.73+1.5%$1.28 billion$356.07 million8.69Heavy News Reporting
Mesoblast logo
MESO
Mesoblast
1.4$9.72+1.1%$1.14 billion$32.16 million-11.05
Adverum Biotechnologies logo
ADVM
Adverum Biotechnologies
1.5$11.37+5.2%$1.11 billion$250,000.00-8.95Analyst Downgrade
TCRR
TCR2 Therapeutics
1.2$32.80+3.3%$1.10 billionN/A-13.44Analyst Downgrade
Sutro Biopharma logo
STRO
Sutro Biopharma
1.1$27.03+4.1%$1.04 billion$42.74 million-24.57Decrease in Short Interest
BDTX
Black Diamond Therapeutics
1.6$26.94+6.2%$969.73 millionN/A-4.45Insider Selling
Heavy News Reporting
CRTX
Cortexyme
1.3$32.61+2.1%$961.93 millionN/A-13.59Analyst Upgrade
Compugen logo
CGEN
Compugen
1.4$13.01+3.8%$890.14 million$17.80 million-35.16Increase in Short Interest
Heavy News Reporting
ATHA
Athira Pharma
1.8$26.55+0.9%$862.48 millionN/A0.00Analyst Upgrade
Vaxart logo
VXRT
Vaxart
1.3$7.18+2.2%$785.99 million$9.86 million-12.17
PRVL
Prevail Therapeutics
1.4$22.93+0.1%$785.26 millionN/A-9.68Decrease in Short Interest
Rubius Therapeutics logo
RUBY
Rubius Therapeutics
1.5$9.48+2.2%$767.16 millionN/A-4.27Analyst Downgrade
Curis logo
CRIS
Curis
0.9$12.80+7.9%$752.86 million$10 million-15.61Analyst Upgrade
Heavy News Reporting
Adaptimmune Therapeutics logo
ADAP
Adaptimmune Therapeutics
1.6$5.72+6.6%$744.22 million$1.12 million-5.78
ORTX
Orchard Therapeutics
1.6$7.08+1.0%$688.63 million$2.51 million-3.87Analyst Revision
Aerie Pharmaceuticals logo
AERI
Aerie Pharmaceuticals
1.7$13.95+1.1%$653.07 million$69.89 million-3.33
Agenus logo
AGEN
Agenus
1.6$3.35+2.1%$637.00 million$150.05 million-3.07Analyst Report
Heavy News Reporting
MeiraGTx logo
MGTX
MeiraGTx
1.4$16.36+0.4%$628.42 million$13.29 million-11.60
DBV Technologies logo
DBVT
DBV Technologies
1.2$5.66+33.9%$621.80 million$14.75 million-2.43Analyst Report
High Trading Volume
Increase in Short Interest
Heavy News Reporting
HARP
Harpoon Therapeutics
1.5$23.40+8.7%$593.89 million$5.78 million-10.99Unusual Options Activity
Heavy News Reporting
DTIL
Precision BioSciences
1.5$11.30+8.1%$593.02 million$22.24 million-5.62High Trading Volume
Increase in Short Interest
AVROBIO logo
AVRO
AVROBIO
1.7$14.39+3.8%$524.53 millionN/A-4.36Analyst Downgrade
High Trading Volume
Heavy News Reporting
Surface Oncology logo
SURF
Surface Oncology
0.9$12.30+2.8%$500.33 million$15.36 million-13.98Increase in Short Interest
Heavy News Reporting
Autolus Therapeutics logo
AUTL
Autolus Therapeutics
1.2$9.02+1.0%$471.30 million$2.91 million-3.14
OYST
Oyster Point Pharma
1.7$17.92+3.5%$463.56 millionN/A-1.64
Proteon Therapeutics logo
PRTO
Proteon Therapeutics
0.8$19.41+3.8%$430.49 millionN/A-16.88
CASI Pharmaceuticals logo
CASI
CASI Pharmaceuticals
1.5$3.39+1.8%$420.17 million$4.13 million-7.53
Solid Biosciences logo
SLDB
Solid Biosciences
1.1$6.48+0.3%$391.71 millionN/A-2.83Analyst Upgrade
Decrease in Short Interest
Jounce Therapeutics logo
JNCE
Jounce Therapeutics
1.6$9.12+14.9%$363.44 million$147.87 million-3.03High Trading Volume
Heavy News Reporting
OCGN
Ocugen
1.1$2.22+1.8%$359.70 millionN/A-1.50Increase in Short Interest
Eiger BioPharmaceuticals logo
EIGR
Eiger BioPharmaceuticals
1.6$11.02+7.6%$358.50 millionN/A-4.53Decrease in Short Interest
IPHA
Innate Pharma
1.1$4.52+1.5%$356.99 million$96.12 million-13.29Increase in Short Interest
Cellular Biomedicine Group logo
CBMG
Cellular Biomedicine Group
0.6$18.11+1.3%$352.75 million$340,000.00-6.40Decrease in Short Interest
INMB
INmune Bio
1.1$24.82+0.4%$333.78 millionN/A-25.59
Voyager Therapeutics logo
VYGR
Voyager Therapeutics
1.7$8.50+4.9%$318.46 million$104.39 million-5.18Analyst Upgrade
CABA
Cabaletta Bio
1.5$13.04+4.4%$313.68 millionN/A-9.52Insider Selling
PDL BioPharma logo
PDLI
PDL BioPharma
1.2$2.47+0.0%$282.14 million$54.76 million-1.86
LOGC
LogicBio Therapeutics
1.3$8.36+1.1%$265.73 millionN/A-5.22Analyst Downgrade
Gritstone Oncology logo
GRTS
Gritstone Oncology
1.5$6.39+6.7%$241.31 million$4.36 million-2.23
GMDA
Gamida Cell
1.4$9.39+0.3%$227.43 millionN/A-6.57Increase in Short Interest
TARA
Protara Therapeutics
1.8$19.41+3.8%$217.63 millionN/A0.00Increase in Short Interest
Heavy News Reporting
AXLA
Axcella Health
1.6$5.69+0.9%$213.61 millionN/A-2.65Analyst Upgrade
Increase in Short Interest
Heavy News Reporting
ERYTECH Pharma logo
ERYP
ERYTECH Pharma
0.5$10.80+1.8%$211.29 millionN/A-2.76
This page was last updated on 1/15/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.